Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Acceleron Pharma (XLRN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Acceleron to Present at Two Upcoming Healthcare Investor Conferences

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics intended to treat serious and rare diseases,...

XLRN : 42.46 (+1.65%)
Celgene (CELG) Q4 Earnings Beat Estimates, Revenues Up Y/Y

Celgene (CELG) Q4 earnings beat estimates on robust revenues, driven by strong sales of Otezla and Revlimid.

CELG : 90.69 (+0.01%)
BLUE : 137.03 (+2.04%)
XLRN : 42.46 (+1.65%)
BMY : 51.67 (+1.65%)
Is a Beat in the Cards for Celgene (CELG) in Q4 Earnings?

Investors are looking forward to Revlimid's performance and updates from the recently announced merger agreement when Celgene Corporation (CELG) reports Q4 results.

CELG : 90.69 (+0.01%)
VRTX : 188.07 (+1.27%)
XLRN : 42.46 (+1.65%)
BMY : 51.67 (+1.65%)
Acceleron Pharma Falls 3.91% on Heavy Volume: Watch For Potential Rebound

Acceleron Pharma (NASDAQ:XLRN) traded in a range yesterday that spanned from a low of $40.01 to a high of $40.18. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of...

XLRN : 42.46 (+1.65%)
Consolidated Research: 2019 Summary Expectations for Marathon Petroleum, AMC Entertainment, JetBlue Airways, Acceleron Pharma, Natera, and AquaVenture -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Marathon Petroleum Corporation...

MPC : 65.15 (+1.73%)
NTRA : 16.55 (+2.35%)
JBLU : 17.96 (-0.66%)
WAAS : 21.26 (+0.85%)
AMC : 13.79 (+1.03%)
XLRN : 42.46 (+1.65%)
Acceleron Announces Pricing of Public Offering of Common Stock

Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics intended to treat serious and rare hematologic,...

XLRN : 42.46 (+1.65%)
Acceleron Announces Publication of Luspatercept Phase 2 Beta-Thalassemia Study Results in Blood

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that...

XLRN : 42.46 (+1.65%)
CELGZ : 0.91 (+7.06%)
Celgene (CELG) Provides Guidance for 2019, Updates Pipeline

Celgene (CELG) announces guidance for 2019, and other pipeline and regulatory updates.

CELG : 90.69 (+0.01%)
BLUE : 137.03 (+2.04%)
XLRN : 42.46 (+1.65%)
BMY : 51.67 (+1.65%)
Acceleron to Webcast Presentation at the 37th Annual J.P. Morgan Healthcare Conference

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that...

JPM : 105.55 (+3.06%)
XLRN : 42.46 (+1.65%)
Acceleron Announces Luspatercept Phase 3 MEDALIST and BELIEVE Presentations Selected for "Best of ASH" by the American Society of Hematology

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced that the presentations of the MEDALIST and BELIEVE Phase 3 trial results of luspatercept in patients with lower-risk myelodysplastic syndromes...

XLRN : 42.46 (+1.65%)
CELGZ : 0.91 (+7.06%)
Celgene (CELG) Announces Various Cancer Data at ASH 2018

Celegne (CELG) presents data from several cancer studies at the annual meeting of American Society of Hematology (ASH).

CELG : 90.69 (+0.01%)
BLUE : 137.03 (+2.04%)
XLRN : 42.46 (+1.65%)
RHHBY : 34.0200 (+0.80%)
Detailed Research: Economic Perspectives on Honeywell International, Tabula Rasa Healthcare, El Pollo Loco, Acceleron Pharma, vTv Therapeutics, and 22nd Century Group -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Honeywell International Inc....

VTVT : 2.37 (-3.27%)
HON : 153.32 (+1.86%)
XLRN : 42.46 (+1.65%)
XXII : 2.55 (+1.19%)
LOCO : 15.21 (+3.54%)
TRHC : 57.97 (+5.15%)
Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 MEDALIST Trial Evaluating Luspatercept in Patients with Myelodysplastic Syndromes at the ASH 2018 Plenary Session

--Regulatory submissions planned in the United States and Europe in the first half of 2019

CELG : 90.69 (+0.01%)
XLRN : 42.46 (+1.65%)
CELGZ : 0.91 (+7.06%)
Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 BELIEVE Trial Evaluating Luspatercept in Adult Patients with Beta-Thalassemia at ASH 2018

--Regulatory submissions planned in the United States and Europe in the first half of 2019

CELG : 90.69 (+0.01%)
XLRN : 42.46 (+1.65%)
CELGZ : 0.91 (+7.06%)
Interesting XLRN Put And Call Options For January 2019

Investors in Acceleron Pharma, Inc. saw new options begin trading this week, for the January 2019 expiration.

XLRN : 42.46 (+1.65%)
Acceleron Receives FDA Fast Track Designation for ACE-083 in Charcot-Marie-Tooth Disease

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that...

XLRN : 42.46 (+1.65%)
Acceleron to Host Conference Call and Webcast to Review MEDALIST and BELIEVE Phase 3 Trial Presentations of Luspatercept at the 60th American Society of Hematology Annual Meeting

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced it will...

XLRN : 42.46 (+1.65%)
Acceleron to Participate in Two Upcoming Healthcare Investor Conferences

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that...

XLRN : 42.46 (+1.65%)
Acceleron Announces Preclinical Presentations on Sotatercept in Pulmonary Arterial Hypertension at the 2018 American Heart Association Scientific Session

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced plans...

XLRN : 42.46 (+1.65%)
Acceleron Announces that Phase 3 Results from the MEDALIST and BELIEVE Trials of Luspatercept will be Presented at the 60th American Society of Hematology Annual Meeting

--- Phase 3 BELIEVE trial results to be shared in oral presentation -

XLRN : 42.46 (+1.65%)

Van Meerten Stock Picks

SecureWorks - Pick of the Day
My Stock Pick of the Day belongs to the security software company SecureWorks (SCWX).
SCWX -0.33
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar